Chukwu Obinna 
Jos, Nigeria – Nigeria’s drug regulator launches an immediate nationwide mop-up of medicines produced by Europharm Laboratories and Eurolink Nigeria Ltd after tests reveal dangerous deficiencies in antibiotic formulations.
In a notice issued on Friday via its official X handle, the National Agency for Food and Drug Administration and Control (NAFDAC) says investigations uncover systematic production and distribution without valid marketing authorisation.
Laboratory analysis shows Linmoxyn (amoxicillin) suspensions contain just 13.9% and 18.4% of required active ingredient, while capsule versions record 48.3% — levels NAFDAC describes as “grossly substandard.”
The findings follow “credible intelligence and regulatory surveillance” at the firms’ facility in Anglo-Jos New Industrial Area.
NAFDAC warns that medicines with inadequate active ingredients risk treatment failure, antimicrobial resistance and patient harm.
Products subject to recall include antibiotics, antimalarials, analgesics and supplements such as Linocloxin, erythromycin preparations, metronidazole tablets, paracetamol, mebendazole, and various vitamins — many bearing NAFDAC numbers despite lacking proper authorisation.
The agency instructs all zonal directors and state coordinators to commence immediate surveillance and removal nationwide and urges distributors, retailers and healthcare workers to halt circulation.
About the Author
Oluwatobi Adu 
Edino Chubiyo Cornelius 
Koko Maxwella 